Boston Scientific Corporation [NYSE: BSX] closed the trading session at $35.70 on 11/06/20. The day’s price range saw the stock hit a low of $35.09, while the highest price level was $35.865. The company report on November 5, 2020 that Boston Scientific Announces November 2020 Conference Schedule.
Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences.
On November 12, 2020, Meghan Scanlon, senior vice president and president, Urology and Pelvic Health, and Susie Lisa, vice president, Investor Relations, will participate in a 40-minute question-and-answer session with the host analyst at the 29th Annual Credit Suisse Virtual Healthcare Conference. The session will begin at approximately 8:00 a.m. EST.
The stocks have a year to date performance of -21.05 percent and weekly performance of 4.17 percent. The stock has been moved at -5.51 percent over the last six months. The stock has performed -11.83 percent around the most recent 30 days and changed -8.41 percent over the most recent 3-months.
If compared to the average trading volume of 8.82M shares, BSX reached to a volume of 11138573 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Boston Scientific Corporation [BSX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BSX shares is $45.08 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BSX stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for Boston Scientific Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 17, 2020. While these analysts kept the previous recommendation, Wolfe Research raised their target price to Peer Perform. The new note on the price target was released on September 11, 2020, representing the official price target for Boston Scientific Corporation stock. Previously, the target price had yet another raise to $40, while SVB Leerink analysts kept a Mkt Perform rating on BSX stock. On April 01, 2020, analysts decreased their price target for BSX shares from 46 to 38.
The Average True Range (ATR) for Boston Scientific Corporation is set at 1.02, with the Price to Sales ratio for BSX stock in the period of the last 12 months amounting to 4.94. The Price to Book ratio for the last quarter was 3.22, with the Price to Cash per share for the same quarter was set at 1.23. Price to Free Cash Flow for BSX in the course of the last twelve months was 54.87 with Quick ratio for the last quarter at 1.40.
BSX stock trade performance evaluation
Boston Scientific Corporation [BSX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.17. With this latest performance, BSX shares dropped by -11.83% in over the last four-week period, additionally sinking by -5.51% over the last 6 months – not to mention a drop of -12.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BSX stock in for the last two-week period is set at 40.10, with the RSI for the last a single of trading hit 44.59, and the three-weeks RSI is set at 41.86 for Boston Scientific Corporation [BSX]. The present Moving Average for the last 50 days of trading for this stock 38.63, while it was recorded at 35.18 for the last single week of trading, and 37.31 for the last 200 days.
Boston Scientific Corporation [BSX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Boston Scientific Corporation [BSX] shares currently have an operating margin of +15.95 and a Gross Margin at +64.08. Boston Scientific Corporation’s Net Margin is presently recorded at +43.78.
Return on Total Capital for BSX is now 8.56, given the latest momentum, and Return on Invested Capital for the company is 25.91. Return on Equity for this stock inclined to 41.59, with Return on Assets sitting at 18.23. When it comes to the capital structure of this company, Boston Scientific Corporation [BSX] has a Total Debt to Total Equity ratio set at 74.59. Additionally, BSX Total Debt to Total Capital is recorded at 42.72, with Total Debt to Total Assets ending up at 33.87. Long-Term Debt to Equity for the company is recorded at 63.90, with the Long-Term Debt to Total Capital now at 36.60.
Reflecting on the efficiency of the workforce at the company, Boston Scientific Corporation [BSX] managed to generate an average of $130,556 per employee. Receivables Turnover for the company is 6.06 with a Total Asset Turnover recorded at a value of 0.42.Boston Scientific Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.90.
Earnings per share (EPS) analysis for Boston Scientific Corporation [BSX] stock
With the latest financial reports released by the company, Boston Scientific Corporation posted 0.46/share EPS, while the average EPS was predicted by analysts to be reported at 0.44/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BSX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Boston Scientific Corporation go to 8.29%.
Boston Scientific Corporation [BSX]: Insider Ownership positions
There are presently around $46,842 million, or 94.70% of BSX stock, in the hands of institutional investors. The top three institutional holders of BSX stocks are: BLACKROCK INC. with ownership of 128,853,990, which is approximately 3.789% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 113,120,042 shares of the stock with an approximate value of $4.04 billion in BSX stocks shares; and CAPITAL WORLD INVESTORS, currently with $3.01 billion in BSX stock with ownership of nearly 4.475% of the company’s market capitalization.
Positions in Boston Scientific Corporation stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 430 institutional holders increased their position in Boston Scientific Corporation [NYSE:BSX] by around 134,898,696 shares. Additionally, 338 investors decreased positions by around 118,785,895 shares, while 128 investors held positions by with 1,058,411,348 shares. The mentioned changes placed institutional holdings at 1,312,095,939 shares, according to the latest SEC report filing. BSX stock had 90 new institutional investments in for a total of 21,215,851 shares, while 72 institutional investors sold positions of 12,069,621 shares during the same period.